Recent Updates
Recently added Catalysts

ADX-626

Phase 1

Undisclosed | Small molecule | Other |ADARx Pharmaceuticals, Inc.|Trials Updated: Sep 10, 2026

ADX-626 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Jul 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment44

FDA Designations

No designations recorded

ADX-626 clinical trials

ADX-626 · 1 trial · 1 indication

Phase 1 1
NCT07081503Phase 1 Study of ADX-626 in Healthy ParticipantsHealthy Adult Participants
RECRUITING44 Analytics
PHASE1RECRUITING
Phase 1 Study of ADX-626 in Healthy Participants
Healthy Adult Participants
NCT0708150344
Unlock trial analytics

Study Endpoints

Primary Endpoints

Safety of ADX-626 in Healthy Participants
Day 1 to Day 365

Incidence, relationship and severity of adverse events and serious adverse events

Secondary Endpoints

Pharmacokinetics (PK) of ADX-626 - Maximum Concentration
Day 1 to Day 29
Pharmacokinetics (PK) of ADX-626 - Time to Maximum Concentration
Day 1 to Day 29
Pharmacokinetics (PK) of ADX-626 - Exposure
Day 1 to Day 29
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
ADX-626EXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
ADX-626DRUGsiRNA duplex oligonucleotide
PlaceboDRUGSaline
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Key Inclusion Criteria: * Age 18 to 45 years at the time of informed consent * Males or women of non-childbearing potential (WONCBP) * Willing to comply with all study requirements while participating * Suitable venous access for blood sampling. * Body weight ≥ 50 kg and a body mass index (BMI) ≤25...

Countries:United Kingdom
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

ADARx Pharmaceuticals, Inc. (ADRX)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ACompanies A to ZEvery biotech and pharma company we track